Mutual of America Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,115
| Closed | -$56K | – | 1607 |
|
|
2022
Q3 | $56K | Buy |
2,115
+238
| +13% | +$6.3K | ﹤0.01% | 1593 |
|
|
2022
Q2 | $83K | Buy |
1,877
+240
| +15% | +$10.6K | ﹤0.01% | 1541 |
|
|
2022
Q1 | $81K | Buy |
1,637
+85
| +5% | +$4.21K | ﹤0.01% | 1561 |
|
|
2021
Q4 | $79K | Buy |
1,552
+15
| +1% | +$764 | ﹤0.01% | 1578 |
|
|
2021
Q3 | $86K | Sell |
1,537
-121
| -7% | -$6.77K | ﹤0.01% | 1564 |
|
|
2021
Q2 | $71K | Buy |
1,658
+110
| +7% | +$4.71K | ﹤0.01% | 1618 |
|
|
2021
Q1 | $65K | Buy |
1,548
+95
| +7% | +$3.99K | ﹤0.01% | 1614 |
|
|
2020
Q4 | $68K | Sell |
1,453
-50
| -3% | -$2.34K | ﹤0.01% | 1566 |
|
|
2020
Q3 | $64K | Buy |
1,503
+1,011
| +205% | +$43.1K | ﹤0.01% | 1504 |
|
|
2020
Q2 | $24K | Buy |
492
+49
| +11% | +$2.39K | ﹤0.01% | 1519 |
|
|
2020
Q1 | $20K | Buy |
443
+82
| +23% | +$3.7K | ﹤0.01% | 1497 |
|
|
2019
Q4 | $22K | Sell |
361
-12
| -3% | -$731 | ﹤0.01% | 1549 |
|
|
2019
Q3 | $21K | Buy |
373
+2
| +0.5% | +$113 | ﹤0.01% | 1560 |
|
|
2019
Q2 | $21K | Buy |
371
+75
| +25% | +$4.25K | ﹤0.01% | 1556 |
|
|
2019
Q1 | $15K | Buy |
296
+21
| +8% | +$1.06K | ﹤0.01% | 1585 |
|
|
2018
Q4 | $11K | Buy |
275
+65
| +31% | +$2.6K | ﹤0.01% | 1596 |
|
|
2018
Q3 | $15K | Buy |
210
+179
| +577% | +$12.8K | ﹤0.01% | 1551 |
|
|
2018
Q2 | $2K | Buy |
+31
| New | +$2K | ﹤0.01% | 1641 |
|